trending Market Intelligence /marketintelligence/en/news-insights/trending/MOtXEYo94p8RkS1QCoWbfg2 content esgSubNav
In This List

Sanofi exits peanut allergy, celiac treatment partnership with Selecta

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Sanofi exits peanut allergy, celiac treatment partnership with Selecta

Sanofi exited a collaboration agreement to develop treatments for peanut allergy and celiac vaccine with Selecta Biosciences Inc., leaving the latter with worldwide rights to intellectual property, data and materials generated through the partnership.

Selecta and Sanofi entered into a license and research collaboration agreement focused on peanut allergy in November 2012. In May 2015, Sanofi exercised an option to extend the agreement to celiac disease.

Sanofi's decision to exit the collaboration follows a strategic review of its R&D portfolio.